These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35678022)

  • 41. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
    Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
    Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.
    Kondrotienė A; Daukša A; Pamedytytė D; Kazokaitė M; Žvirblienė A; Daukšienė D; Simanavičienė V; Klimaitė R; Golubickaitė I; Stakaitis R; Šarauskas V; Verkauskienė R; Žilaitienė B
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
    Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
    Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma.
    Wang Y; Zhou S; Wang D; Wei T; Zhu J; Li Z
    Front Endocrinol (Lausanne); 2021; 12():737638. PubMed ID: 34803909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A diagnostic model based on DNA methylation haplotype block characteristics for identifying papillary thyroid carcinoma from thyroid adenoma.
    Xu D; Lai Y; Liu H; Li H; Feng N; Liu Y; Gong C; Zhang Y; Zhou J; Shen Y
    Transl Res; 2024 Feb; 264():76-84. PubMed ID: 37863284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SuperSonic shear imaging for the differentiation between benign and malignant thyroid nodules: a meta-analysis.
    Chen Y; Dong B; Jiang Z; Cai Q; Huang L; Huang H
    J Endocrinol Invest; 2022 Jul; 45(7):1327-1339. PubMed ID: 35229278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of high b-value (2000 sec/mm2) DWI with RESOLVE in differentiating papillary thyroid carcinomas and papillary thyroid microcarcinomas from benign thyroid nodules.
    Wang Q; Guo Y; Zhang J; Shi L; Ning H; Zhang X; Lu Y
    PLoS One; 2018; 13(7):e0200270. PubMed ID: 30020961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
    Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
    Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
    [No Abstract]   [Full Text] [Related]  

  • 49. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas.
    Baldane S; Ipekci SH; Sozen M; Kebapcilar L
    Asian Pac J Cancer Prev; 2015; 16(7):2671-4. PubMed ID: 25854344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
    Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
    Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
    OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
    Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
    Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation.
    Vierlinger K; Mansfeld MH; Koperek O; Nöhammer C; Kaserer K; Leisch F
    BMC Med Genomics; 2011 Apr; 4():30. PubMed ID: 21470421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased serum exosomal miR-29a expression and its clinical significance in papillary thyroid carcinoma.
    Wen Q; Wang Y; Li X; Jin X; Wang G
    J Clin Lab Anal; 2021 Jan; 35(1):e23560. PubMed ID: 33368640
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Duan Y; Zhang Y; Peng W; Jiang P; Deng Z; Wu C
    Pharmazie; 2020 Jun; 75(6):266-270. PubMed ID: 32539923
    [No Abstract]   [Full Text] [Related]  

  • 56. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
    Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
    Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Digital image-assisted quantitative nuclear analysis improves diagnostic accuracy of thyroid fine-needle aspiration cytology.
    Chain K; Legesse T; Heath JE; Staats PN
    Cancer Cytopathol; 2019 Aug; 127(8):501-513. PubMed ID: 31150162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
    Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
    Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA signature predicts survival in papillary thyroid carcinoma.
    Chengfeng X; Gengming C; Junjia Z; Yunxia L
    J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma.
    Cui W; Xuan T; Liao T; Wang Y
    Front Oncol; 2024; 14():1410110. PubMed ID: 39169938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.